Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter ended September 30, 2019
Filing Date: October 29, 2019
This filing serves as a cover document announcing the Company's third-quarter 2019 results. The detailed financial data and press release are provided as Exhibits 99.1 and 99.2, which are not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached Exhibits (99.1 and 99.2).
The Company utilizes the following non-GAAP financial measures to supplement IFRS reporting:
- EBITDA (Operating income excluding interest, taxes, depreciation, and amortization)
- Delivered operating income (Earnings before interest and taxes)
- Free cash flow
- Results presented in constant currency
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached Press Release (Exhibit 99.1) for period-over-period comparisons.
Guidance, Outlook, and Risks
Management Commentary: The Company states that non-GAAP measures are included to enhance understanding of current performance and future prospects, as well as to ensure consistency with historical reporting. These measures are not intended to substitute for GAAP/IFRS measures.
Reconciliation: Reconciliations between non-GAAP measures and the most comparable IFRS measures are included in the attached Press Release and the Cash Flow Statement.
Risks and Contingencies: The filing text does not explicitly detail specific risks or contingencies beyond the standard disclaimer regarding the non-GAAP measures and the status of the exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2019 revenue, EBITDA, and free cash flow figures.
- Examine Exhibit 99.2 for the detailed financial tables and reconciliation of non-GAAP to IFRS measures.
- Verify the impact of currency fluctuations by comparing reported results with constant currency results in the exhibits.
- Confirm the status of the exhibits, noting they are furnished but not "filed" for liability purposes under Section 18 of the Exchange Act.